Supreme Court justices appeared skeptical of arguments seeking to limit the legal protections afforded to generic drug manufacturers employing a practice known as “skinny labeling,” a tactic used...
Skinny labeling involves generic companies seeking regulatory approval to market a drug for a specific use outlined in a brand-name drug’s patent, while deliberately avoiding marketing for other...
The case centers on Hikma Pharmaceuticals’ attempt to market a generic version of Amarin’s Vascepa, a drug originally approved to lower triglyceride levels.
Supreme Court justices appeared skeptical of arguments seeking to limit the legal protections afforded to generic drug manufacturers employing a practice known as “skinny labeling,” a tactic used to navigate patent restrictions on branded medications. The justices heard oral arguments on April 29, 2026, in the case of Hikma v. Amarin, and did not signal an inclination to alter existing legal standards regarding the practice, according to reporting from STAT News.
Skinny labeling involves generic companies seeking regulatory approval to market a drug for a specific use outlined in a brand-name drug’s patent, while deliberately avoiding marketing for other uses still protected by patent. This allows generic manufacturers to enter the market without directly infringing on the brand-name drug’s broader patent coverage.
The case centers on Hikma Pharmaceuticals’ attempt to market a generic version of Amarin’s Vascepa, a drug originally approved to lower triglyceride levels. Amarin sued Hikma, alleging that the generic company’s labeling—which avoided mentioning the drug’s benefits for cardiovascular health, a use covered by Amarin’s patent—was still an act of induced infringement because Hikma’s marketing materials referenced the brand-name drug and overall sales figures that included the patented indication.
The Hatch-Waxman Act and the Rise of Skinny Labeling
Skinny labeling emerged as a key strategy for generic companies following the passage of the Hatch-Waxman Act in 1984. This landmark legislation established a pathway for streamlined approval of generic drugs, aiming to increase competition and lower prescription drug costs. The law created mechanisms by which generic drugs could more readily enter the marketplace, and skinny labeling became one avenue for achieving that goal.
From Instagram — related to Skinny Labeling, Waxman Act
As STAT News reported, the tactic is intended to foster competition and benefit consumers by allowing access to lower-cost generic alternatives, even when patents on certain uses of a drug remain in effect. By carefully defining the approved indications for the generic drug, manufacturers aim to avoid direct patent infringement lawsuits.
Supreme Court’s Stance on Induced Infringement
The core legal question before the Supreme Court revolves around the standard for “induced infringement.” Amarin argues that Hikma’s marketing, even with the limited labeling, intentionally encouraged doctors to prescribe the generic drug for uses still covered by Amarin’s patent, thus constituting induced infringement. Hikma contends that its labeling was carefully crafted to avoid infringing on the patent and that it should not be held liable for how doctors ultimately prescribe the drug.
“Although it’s always difficult to predict the outcome based on oral argument, the questions from the Justices (and the responses from the parties) suggested that a new standard for induced infringement is unlikely to be adopted.”
Supreme Court hands down order that could affect the Pa. GOP Senate primary
Chad A. Landmon, Corey M. Casey, Pharm.D., Mark T. Deming, Andrew M. Solomon, Polsinelli PC
According to analysis from Polsinelli PC, the Supreme Court justices did not appear inclined to create a new rule for induced infringement in the pharmaceutical industry. The firm’s analysis of the oral arguments suggests the court may be interested in weighing in on the patent merits surrounding skinny labeling, but also noted the possibility that the court could punt on the issue and focus instead on the plausibility standard for pleadings.
The Solicitor General submitted a brief supporting Hikma’s petition after the Court requested the views of the United States, further indicating potential support for the generic manufacturer’s position. The Court granted review on January 16, 2026.
Potential Impact of the Ruling
The outcome of Hikma v. Amarin could have significant implications for the pharmaceutical industry. A ruling favoring Amarin could make it more difficult for generic companies to utilize skinny labeling, potentially slowing down the entry of lower-cost generics into the market. Conversely, a ruling in favor of Hikma would reinforce the legality of the practice and encourage continued use of skinny labeling as a pathway to increased competition.
Amarin Skinny Labeling
An opinion in the case is expected by the end of June 2026. The decision will likely provide clarity on the boundaries of permissible communications and marketing practices for generic drugs with skinny labels, impacting the balance between patent rights and access to affordable medications.
